We can't find the internet
Attempting to reconnect
25758.1 PFLS-LS
Developing a therapeutic vaccination targeting pruritus in equine
Zusammenfassung
Developing a therapeutic vaccination targeting pruritus in equine
Weitere Texte
Abstract
This research project#s objective is to evaluate a potential benefit of blocking IL-31- mediated pruritus in allergic dermatitis of the horse. The most common allergic dermatitis of horses is the so-called insect bite hypersensitivity (IBH), an allergy against insect bites. Therefore, we will develop a therapeutic vaccine against aiming at inducing anti-IL-31 auto-antibodies. This vaccine will be compared against a monotherapy of the already existing vaccine eIL-5-VLP and a combination therapy of eIL-5-VLP and eIL-31- VLP in a placebo controlled randomized double blind phase II study. Furthermore, the vaccine production will be optimized, the clinical proof of efficacy will be obtained, and long-term safety profiles of the vaccines will be studied.
Beteiligte
Antonia Gabriel
Wirtschaftspartner
antonia@evax.ch
Evax AG Antonia Gabriel Hörnlistrasse 3 9542 Münchwilen TG CH
Thomas Kündig
Kontaktperson
thomas.kuendig@usz.ch
USZ Universitätsspital Zürich Dermatologie Thomas Kündig Gloriastrasse 31 8091 Zürich ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2017-03-31
- Enddatum
- 2019-11-30
- Bewilligte Gesamtkosten
- CHF 374584.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%